查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1496203

CAR-T疗法市场：2024-2034

CAR-T Therapy Market Report 2024-2034
出版日期: | 出版商: Visiongain | 英文 337 Pages | 商品交期: 最快1-2个工作天内

价格

预计到 2034 年，全球 CAR-T 疗法市场规模将以 35.9% 的复合年增长率成长。

新兴市场采用 CAR-T 细胞疗法推动市场成长：

新兴市场对 CAR-T 细胞疗法的采用速度略慢于已开发经济体。造成这种情况的主要原因是CAR-T细胞疗法价格昂贵，难以建立必要的基础设施和专业知识。然而，在未来几年中，可能会出现一些变量，这些变量将有助于CAR-T细胞疗法在新兴国家的广泛采用。人口老化、都市化和不健康的生活方式导致中国、印度和巴西等一些新兴国家的癌症发生率显着增加。由于疾病负担不断增加，CAR-T 细胞疗法等先进癌症治疗变得越来越必要。

在新兴国家，生物製药公司正在与当地公司和研究机构合作并建立伙伴关係，以加速 CAR-T 细胞疗法的开发、生产和分销。这种伙伴关係可以帮助解决行政和法律问题。为了促进 CAR-T 细胞疗法的研究和批准，中国和印度等新兴市场正在製定监管框架和指南，这可能会促使投资和采用的增加。

2023年，生物製药公司加强利用研究合作与策略性投资，加速CAR-T细胞疗法在新兴地区的采用。以下是 2023 年显着进步和业务支出的范例。

Novartis宣布计划于 2023 年初在新加坡建造 CAR-T 细胞疗法生产设施。该工厂将服务亚太地区，包括中国和印度等新兴市场。该公司还扩大了与Guangzhou Bio-Ree Cell Therapy Co. 的合作伙伴关係，以进一步在中国研究和销售CAR-T细胞疗法。

Gilead Sciences与印度生物技术公司 IndiaBioScience 于 2023 年 3 月建立策略合作伙伴关係，为印度市场研究和生产 CAR-T 细胞疗法。这项合作关係旨在利用Gilead的 CAR-T 细胞治疗技术和 IndiaBioScience 在细胞治疗製造方面的经验，将这些药物带给印度患者。

本报告调查了全球CAR-T 疗法市场，并提供了市场概况、影响市场成长和市场机会的因素分析、市场规模趋势和预测、各个细分市场/地区/主要国家的详细分析，总结了竞争格局、概况各大公司等

目录

第1章 报告概述

第2章 执行摘要

第3章 市场概况

  • 主要发现
  • 市场动态
  • 影响分析
    • 市场驱动力
    • 市场制约因素
    • 市场机会
  • 供应链分析
  • 监管框架
  • COVID-19 影响分析
  • 波特五力分析
  • PEST分析

第4章 CAR-T 疗法市场分析：依目标抗原

  • 主要发现
  • 市场吸引力指数
  • 市场规模趋势和预测
  • CD19/CD22
  • BCMA
  • 其他
    • 市场规模趋势与预测：依地区
    • 市占率：依地区

第5章 CAR-T 疗法市场分析：依类型

  • 主要发现
  • 市场吸引力指数
  • 市场规模趋势和预测
  • Abecma
  • Yescarta
  • Kymriah
  • Tecartus
  • 其他
    • 市场规模趋势与预测：依地区
    • 市占率：依地区

第6章 CAR-T 疗法市场分析：依适应症分类

  • 主要发现
  • 市场吸引力指数
  • 市场规模趋势和预测
  • 瀰漫性大 B 细胞淋巴瘤 (DLBCL)
  • 急性淋巴性白血病（ALL）
  • 滤泡性淋巴瘤
  • 多发性骨髓瘤 (MM)
  • 其他
    • 市场规模趋势与预测：依地区
    • 市占率：依地区

第7章 CAR-T 疗法市场分析：依最终使用者分类

  • 主要发现
  • 市场吸引力指数
  • 市场规模趋势和预测
  • 医院
  • 专科诊所
  • 其他
    • 市场规模趋势与预测：依地区
    • 市占率：依地区

第8章 CAR-T 疗法市场分析：依患者分类

  • 主要发现
  • 市场吸引力指数
  • 市场规模趋势和预测
  • 孩子
  • 成人
  • 老年人
    • 市场规模趋势与预测：依地区
    • 市占率：依地区

第9章 CAR-T 疗法市场分析：依地区

  • 主要发现
  • 市场规模趋势和预测

第10章 北美CAR-T疗法市场分析

第11章 欧洲CAR-T疗法市场分析

第12章 亚太CAR-T疗法市场分析

第13章 拉美CAR-T疗法市场分析

第14章 中东及非洲CAR-T疗法市场分析

第15章 公司简介

  • 竞争格局
  • 管道分析
  • 战略视角
  • Gilead Sciences Inc.
  • Novartis AG
  • Bristol Myers Squibb
  • Johnson & Johnson Services, Inc.
  • AbbVie Inc.
  • Amgen Inc.
  • BioNTech S.E.
  • Bluebird bio, Inc.
  • Caribou Biosciences Inc.
  • GSK plc
  • CARsgen Therapeutics Holdings Limited
  • Pfizer Inc.
  • Autolus Therapeutics
  • Intellia Therapeutics
  • 2seventy bio, Inc.

第16章 一般评论/建议

  • Visiongain 的一般讨论
  • 对进入市场的企业的建议
Product Code: PHA1341

The global CAR-T Therapy market is projected to grow at a CAGR of 35.9% by 2034

The CAR-T Therapy Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Adoption of CAR-T Cell Therapy in Emerging Markets Driving Market Growth

Compared to developed economies, the adoption of CAR-T cell therapy in emerging markets has been somewhat sluggish. This is mostly because these therapies come with hefty costs, and it cannot be easy to set up the required infrastructure and expertise. However, in the upcoming years, a number of variables may contribute to the growing use of CAR-T cell therapy in emerging countries. Aging populations, urbanization, and the adoption of unhealthy lifestyles are all contributing to a notable increase in cancer incidence in several emerging economies, including China, India, and Brazil. Advanced cancer therapies, such as CAR-T cell therapies, are becoming more and more necessary due to the growing burden of disease.

In emerging countries, biopharmaceutical companies are collaborating and forming partnerships with local companies and institutes to expedite the development, production, and distribution of CAR-T cell treatments. These partnerships can assist in resolving administrative and legal issues. In order to expedite the research and approval of CAR-T cell treatments, several emerging markets, like China and India, have put in place regulatory frameworks and guidelines. This could lead to increased investment and uptake.

Biopharmaceutical companies are stepping up their efforts in 2023 to leverage collaborations and strategic investments to boost the uptake of CAR-T cell treatments in emerging regions. The following are some noteworthy advancements and business expenditures in this field, particularly for 2023.

Novartis announced plans to build a production facility for CAR-T cell treatment in Singapore at the beginning of 2023. This plant will cater to the Asia-Pacific region, which includes developing markets such as China and India. To further research and market CAR-T cell therapies in China, the business increased its partnership with Guangzhou Bio-Ree Cell Therapy Co., Ltd.

Gilead Sciences and IndiaBioScience, an Indian biotechnology business, formed a strategic alliance in March 2023 to research and produce CAR-T cell treatments for the Indian market. The partnership intends to use Gilead's CAR-T cell therapy technology and IndiaBioScience's experience in cell therapy manufacturing to provide these medicines to patients in India.

In early 2023, Bristol Myers Squibb announced plans to open a CAR-T cell therapy production facility in China, working with regional businesses. Additionally, it has been claimed that the company is in talks to introduce its CAR-T cell therapies to regulatory bodies in Brazil and other Latin American countries.

Janssen announced in February 2023 that it will be extending its partnership with Nanjing Legend Biotech to include possible new targets and indications for the development and commercialization of CAR-T cell treatments in China. The business is also looking into joint ventures with regional businesses and organizations in other developing nations, such as Russia and India.

In early 2023, Poseida Therapeutics (China) reported encouraging preliminary results from its Phase 1 trial assessing P-BCMA-ALLO1, a candidate for allogeneic CAR-T cell treatment, in patients with relapsed or refractory multiple myeloma.

Chinese biopharmaceutical startup Cellular Biomedicine Group is developing autologous CAR-T cell treatment candidates for different cancer types in China, with hopes to start pivotal studies in 2023.

The investments above and collaborations underscore the increasing acknowledgment of the possibilities of CAR-T cell therapies in developing economies and the endeavours of biopharmaceutical corporations to get a foothold in these areas. Through creating manufacturing facilities, utilizing local expertise, and managing regulatory procedures, these firms seek to expand patients' access to these cutting-edge cancer medicines in developing economies.

What Questions Should You Ask before Buying a Market Research Report?

How is the CAR-T therapy market evolving?

What is driving and restraining the CAR-T therapy market?

How will each CAR-T therapy submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each CAR-T therapy submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading CAR-T therapy markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the CAR-T therapy projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of CAR-T therapy projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the CAR-T therapy market?

Where is the CAR-T therapy market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the CAR-T Therapy market today, and over the next 10 years:

Our 337-page report provides 117 tables and 192 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising CAR-T Therapy prices and recent developments.

Segments Covered in the Report

Indication

Diffuse Large B-Cell Lymphoma (DLBCL)

Acute Lymphoblastic Leukaemia (ALL)

Follicular Lymphoma

Multiple Myeloma (MM)

Others

Type

Abecma

Yescarta

Kymriah

Tecartus

Others

Target Antigens

CD19/CD22

BCMA

Others

End-users

Hospitals

Specialty Clinics

Other End-users

Patient

Children

Adults

Seniors

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and U.S., China, Brazil, and Singapore leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Spain

Italy

Rest of Europe

Asia Pacific

China

Japan

Singapore

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

MEA

GCC

Israel

Rest of MEA

The report also includes profiles for some of the leading companies in the CAR-T Therapy Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

2seventy bio, Inc.

AbbVie Inc.

Amgen Inc.

Autolus Therapeutics

BioNTech S.E.

Bluebird bio Inc.

Bristol-Myers Squibb

Caribou Biosciences, Inc.

CARsgen Therapeutics Holdings Limited

Gilead Sciences Inc.

GSK plc

Intellia Therapeutics

Johnson & Johnson Services, Inc.

Novartis AG

Pfizer Inc.

Overall world revenue for CAR-T Therapy Market, 2024 to 2034 in terms of value the market will surpass US$1,480 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the CAR-T Therapy Market, 2024 to 2034 report help you?

In summary, our 330+ page report provides you with the following knowledge:

Revenue forecasts to 2034 for CAR-T Therapy Market, 2024 to 2034, with forecasts for indication, type, target antigens, end-users and patient, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 20 key national markets - See forecasts for the CAR-T Therapy Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, Singapore, Japan, and Australia, among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for are Gilead Sciences Inc., Novartis AG, Bristol-Myers Squibb, Johnson & Johnson Services, Inc., AbbVie Inc., Amgen Inc., BioNTech S.E., Bluebird bio Inc., Caribou Biosciences, Inc., GSK plc, CARsgen Therapeutics Holdings Limited, Pfizer Inc., Autolus Therapeutics, Intellia Therapeutics, and 2seventy bio, Inc. of the major companies involved in the CAR-T Therapy Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the CAR-T Therapy Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to CAR-T Therapy Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
  • 3.3 Impact Analysis
    • 3.3.1 Market Driving Factors
      • 3.3.1.1 Increasing Cancer Incidence
      • 3.3.1.2 Increasing Research and Development to Enhance Treatment with CAR-T Cell Therapy
      • 3.3.1.3 Growing Ongoing Clinical Trials and Regulatory Approvals
    • 3.3.2 Market Restraining Factors
      • 3.3.2.1 High Cost of CAR-T Cell Therapy
      • 3.3.2.2 Safety Concerns Remain a Critical Aspect Influencing the CAR-T Cell Therapy
    • 3.3.3 Market Opportunities
      • 3.3.3.1 Expanding Target Indications
      • 3.3.3.2 Increasing Adoption of CAR-T Cell Therapy in Emerging Markets
  • 3.4 Supply Chain Analysis
  • 3.5 Regulatory Framework
  • 3.6 COVID-19 Impact Analysis
  • 3.7 Porter Analysis
  • 3.8 PEST Analysis
    • 3.8.1 Political Factors:
    • 3.8.2 Economic Factors:
    • 3.8.3 Social Factors:
    • 3.8.4 Technological Factors:

4 CAR-T Therapy Market Analysis by Target Antigens

  • 4.1 Key Findings
  • 4.2 Target Antigens Segment: Market Attractiveness Index
  • 4.3 CAR-T Therapy Market Size Estimation and Forecast by Target Antigens
  • 4.4 CD19/CD22
    • 4.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 4.4.2 Market Share by Region, 2024 & 2034 (%)
  • 4.5 BCMA
    • 4.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 4.5.2 Market Share by Region, 2024 & 2034 (%)
  • 4.6 Others
    • 4.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 4.6.2 Market Share by Region, 2024 & 2034 (%)

5 CAR-T Therapy Market Analysis by Type

  • 5.1 Key Findings
  • 5.2 Type Segment: Market Attractiveness Index
  • 5.3 CAR-T Therapy Market Size Estimation and Forecast by Type
  • 5.4 Abecma
    • 5.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.4.2 Market Share by Region, 2024 & 2034 (%)
  • 5.5 Yescarta
    • 5.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.5.2 Market Share by Region, 2024 & 2034 (%)
  • 5.6 Kymriah
    • 5.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.6.2 Market Share by Region, 2024 & 2034 (%)
  • 5.7 Tecartus
    • 5.7.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.7.2 Market Share by Region, 2024 & 2034 (%)
  • 5.8 Other Types
    • 5.8.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.8.2 Market Share by Region, 2024 & 2034 (%)

6 CAR-T Therapy Market Analysis by Indication

  • 6.1 Key Findings
  • 6.2 Indication Segment: Market Attractiveness Index
  • 6.3 CAR-T Therapy Market Size Estimation and Forecast by Indication
  • 6.4 Diffuse Large B-Cell Lymphoma (DLBCL)
    • 6.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.4.2 Market Share by Region, 2024 & 2034 (%)
  • 6.5 Acute Lymphoblastic Leukaemia (ALL)
    • 6.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.5.2 Market Share by Region, 2024 & 2034 (%)
  • 6.6 Follicular Lymphoma
    • 6.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.6.2 Market Share by Region, 2024 & 2034 (%)
  • 6.7 Multiple Myeloma (MM)
    • 6.7.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.7.2 Market Share by Region, 2024 & 2034 (%)
  • 6.8 Other Indication
    • 6.8.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.8.2 Market Share by Region, 2024 & 2034 (%)

7 CAR-T Therapy Market Analysis by End-users

  • 7.1 Key Findings
  • 7.2 End-users Segment: Market Attractiveness Index
  • 7.3 CAR-T Therapy Market Size Estimation and Forecast by End-users
  • 7.4 Hospitals
    • 7.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.4.2 Market Share by Region, 2024 & 2034 (%)
  • 7.5 Specialty Clinics
    • 7.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.5.2 Market Share by Region, 2024 & 2034 (%)
  • 7.6 Other End-users
    • 7.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.6.2 Market Share by Region, 2024 & 2034 (%)

8 CAR-T Therapy Market Analysis by Patient

  • 8.1 Key Findings
  • 8.2 Patient Segment: Market Attractiveness Index
  • 8.3 CAR-T Therapy Market Size Estimation and Forecast by Patient
  • 8.4 Children
    • 8.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 8.4.2 Market Share by Region, 2024 & 2034 (%)
  • 8.5 Adults
    • 8.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 8.5.2 Market Share by Region, 2024 & 2034 (%)
  • 8.6 Seniors
    • 8.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 8.6.2 Market Share by Region, 2024 & 2034 (%)

9 CAR-T Therapy Market Analysis by Region

  • 9.1 Key Findings
  • 9.2 Regional Market Size Estimation and Forecast

10 North America CAR-T Therapy Market Analysis

  • 10.1 Key Findings
  • 10.2 North America CAR-T Therapy Market Attractiveness Index
  • 10.3 North America CAR-T Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 10.4 North America CAR-T Therapy Market Size Estimation and Forecast by Country
  • 10.5 North America CAR-T Therapy Market Size Estimation and Forecast by Target Antigens
  • 10.6 North America CAR-T Therapy Market Size Estimation and Forecast by Type
  • 10.7 North America CAR-T Therapy Market Size Estimation and Forecast by Indication
  • 10.8 North America CAR-T Therapy Market Size Estimation and Forecast by End-users
  • 10.9 North America CAR-T Therapy Market Size Estimation and Forecast by Patients
  • 10.10 U.S. CAR-T Therapy Market Analysis
  • 10.11 Canada CAR-T Therapy Market Analysis

11 Europe CAR-T Therapy Market Analysis

  • 11.1 Key Findings
  • 11.2 Europe CAR-T Therapy Market Attractiveness Index
  • 11.3 Europe CAR-T Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 11.4 Europe CAR-T Therapy Market Size Estimation and Forecast by Country
  • 11.5 Europe CAR-T Therapy Market Size Estimation and Forecast by Target Antigens
  • 11.6 Europe CAR-T Therapy Market Size Estimation and Forecast by Type
  • 11.7 Europe CAR-T Therapy Market Size Estimation and Forecast by Indication
  • 11.8 Europe CAR-T Therapy Market Size Estimation and Forecast by End-users
  • 11.9 Europe CAR-T Therapy Market Size Estimation and Forecast by Patients
  • 11.10 Germany CAR-T Therapy Market Analysis
  • 11.11 UK CAR-T Therapy Market Analysis
  • 11.12 France CAR-T Therapy Market Analysis
  • 11.13 Italy CAR-T Therapy Market Analysis
  • 11.14 Spain CAR-T Therapy Market Analysis
  • 11.15 Rest of Europe CAR-T Therapy Market Analysis

12 Asia Pacific CAR-T Therapy Market Analysis

  • 12.1 Key Findings
  • 12.2 Asia Pacific CAR-T Therapy Market Attractiveness Index
  • 12.3 Asia Pacific CAR-T Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 12.4 Asia Pacific CAR-T Therapy Market Size Estimation and Forecast by Country
  • 12.5 Asia Pacific CAR-T Therapy Market Size Estimation and Forecast by Target Antigens
  • 12.6 Asia Pacific CAR-T Therapy Market Size Estimation and Forecast by Type
  • 12.7 Asia Pacific CAR-T Therapy Market Size Estimation and Forecast by Indication
  • 12.8 Asia Pacific CAR-T Therapy Market Size Estimation and Forecast by End-users
  • 12.9 Asia Pacific CAR-T Therapy Market Size Estimation and Forecast by Patients
  • 12.10 China CAR-T Therapy Market Analysis
  • 12.11 Japan CAR-T Therapy Market Analysis
  • 12.12 Singapore CAR-T Therapy Market Analysis
  • 12.13 Australia CAR-T Therapy Market Analysis
  • 12.14 South Korea CAR-T Therapy Market Analysis
  • 12.15 Rest of Asia Pacific CAR-T Therapy Market Analysis

13 Latin America CAR-T Therapy Market Analysis

  • 13.1 Key Findings
  • 13.2 Latin America CAR-T Therapy Market Attractiveness Index
  • 13.3 Latin America CAR-T Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 13.4 Latin America CAR-T Therapy Market Size Estimation and Forecast by Country
  • 13.5 Latin America CAR-T Therapy Market Size Estimation and Forecast by Target Antigens
  • 13.6 Latin America CAR-T Therapy Market Size Estimation and Forecast by Type
  • 13.7 Latin America CAR-T Therapy Market Size Estimation and Forecast by Indication
  • 13.8 Latin America CAR-T Therapy Market Size Estimation and Forecast by End-users
  • 13.9 Latin America CAR-T Therapy Market Size Estimation and Forecast by Patients
  • 13.10 Brazil CAR-T Therapy Market Analysis
  • 13.11 Mexico CAR-T Therapy Market Analysis
  • 13.12 Rest of Latin America CAR-T Therapy Market Analysis

14 MEA CAR-T Therapy Market Analysis

  • 14.1 Key Findings
  • 14.2 MEA CAR-T Therapy Market Attractiveness Index
  • 14.3 MEA CAR-T Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 14.4 MEA CAR-T Therapy Market Size Estimation and Forecast by Country
  • 14.5 MEA CAR-T Therapy Market Size Estimation and Forecast by Target Antigens
  • 14.6 MEA CAR-T Therapy Market Size Estimation and Forecast by Type
  • 14.7 MEA CAR-T Therapy Market Size Estimation and Forecast by Indication
  • 14.8 MEA CAR-T Therapy Market Size Estimation and Forecast by End-users
  • 14.9 MEA CAR-T Therapy Market Size Estimation and Forecast by Patients
  • 14.10 Israel CAR-T Therapy Market Analysis
  • 14.11 GCC CAR-T Therapy Market Analysis
  • 14.12 Rest of MEA CAR-T Therapy Market Analysis

15 Company Profiles

  • 15.1 Competitive Landscape, 2023
  • 15.2 Pipeline analysis
  • 15.3 Strategic Outlook
  • 15.4 Gilead Sciences Inc.
    • 15.4.1 Company Snapshot
    • 15.4.2 Company Overview
    • 15.4.3 Financial Analysis
      • 15.4.3.1 Net Revenue, 2018-2023
      • 15.4.3.2 R&D, 2018-2023
      • 15.4.3.3 Regional Market Shares, 2023
    • 15.4.4 Product Benchmarking
    • 15.4.5 Strategic Outlook
    • 15.4.6 SWOT Analysis
  • 15.5 Novartis AG
    • 15.5.1 Company Snapshot
    • 15.5.2 Company Overview
    • 15.5.3 Financial Analysis
      • 15.5.3.1 Net Revenue, 2018-2023
      • 15.5.3.2 R&D, 2018-2023
      • 15.5.3.3 Regional Market Shares, 2023
    • 15.5.4 Product Benchmarking
    • 15.5.5 Strategic Outlook
    • 15.5.6 SWOT Analysis
  • 15.6 Bristol Myers Squibb
    • 15.6.1 Company Snapshot
    • 15.6.2 Company Overview
    • 15.6.3 Financial Analysis
      • 15.6.3.1 Net Revenue, 2018-2023
      • 15.6.3.2 R&D, 2018-2023
      • 15.6.3.3 Regional Market Shares, 2023
    • 15.6.4 Product Benchmarking
    • 15.6.5 Strategic Outlook
    • 15.6.6 SWOT Analysis
  • 15.7 Johnson & Johnson Services, Inc.
    • 15.7.1 Company Snapshot
    • 15.7.2 Company Overview
    • 15.7.3 Financial Analysis
      • 15.7.3.1 Net Revenue, 2017-2022
      • 15.7.3.2 R&D, 2017-2022
      • 15.7.3.3 Regional Market Shares, 2022
    • 15.7.4 Product Benchmarking
    • 15.7.5 SWOT Analysis
  • 15.8 AbbVie Inc.
    • 15.8.1 Company Snapshot
    • 15.8.2 Company Overview
    • 15.8.3 Financial Analysis
      • 15.8.3.1 Net Revenue, 2018-2023
      • 15.8.3.2 R&D, 2018-2023
      • 15.8.3.3 Regional Market Shares, 2023
    • 15.8.4 Product Benchmarking
    • 15.8.5 Strategic Outlook
  • 15.9 Amgen Inc.
    • 15.9.1 Company Snapshot
    • 15.9.2 Company Overview
    • 15.9.3 Financial Analysis
      • 15.9.3.1 Net Revenue, 2018-2023
      • 15.9.3.2 R&D, 2018-2023
      • 15.9.3.3 Regional Market Shares, 2023
    • 15.9.4 Product Benchmarking
  • 15.10 BioNTech S.E.
    • 15.10.1 Company Snapshot
    • 15.10.2 Company Overview
    • 15.10.3 Financial Analysis
      • 15.10.3.1 Net Revenue, 2018-2023
      • 15.10.3.2 R&D, 2018-2023
    • 15.10.4 Product Benchmarking
  • 15.11 Bluebird bio, Inc.
    • 15.11.1 Company Snapshot
    • 15.11.2 Company Overview
    • 15.11.3 Financial Analysis
      • 15.11.3.1 Net Revenue, 2017-2022
      • 15.11.3.2 R&D, 2017-2022
    • 15.11.4 Product Benchmarking
  • 15.12 Caribou Biosciences Inc.
    • 15.12.1 Company Snapshot
    • 15.12.2 Company Overview
    • 15.12.3 Financial Analysis
      • 15.12.3.1 Net Revenue, 2019-2023
      • 15.12.3.2 R&D, 2019-2023
    • 15.12.4 Product Benchmarking
    • 15.12.5 Strategic Outlook
  • 15.13 GSK plc
    • 15.13.1 Company Snapshot
    • 15.13.2 Company Overview
    • 15.13.3 Financial Analysis
      • 15.13.3.1 Net Revenue, 2018-2023
      • 15.13.3.2 R&D, 2018-2023
      • 15.13.3.3 Regional Market Shares, 2023
    • 15.13.4 Product Benchmarking
  • 15.14 CARsgen Therapeutics Holdings Limited
    • 15.14.1 Company Snapshot
    • 15.14.2 Company Overview
    • 15.14.3 Pipeline Product Benchmarking
    • 15.14.4 Strategic Outlook
  • 15.15 Pfizer Inc.
    • 15.15.1 Company Snapshot
    • 15.15.2 Company Overview
    • 15.15.3 Financial Analysis
      • 15.15.3.1 Net Revenue, 2018-2023
      • 15.15.3.2 R&D, 2018-2023
      • 15.15.3.3 Regional Market Shares, 2023
    • 15.15.4 Pipeline Product Benchmarking
    • 15.15.5 Strategic Outlook
  • 15.16 Autolus Therapeutics
    • 15.16.1 Company Snapshot
    • 15.16.2 Company Overview
    • 15.16.3 Pipeline Product Benchmarking
    • 15.16.4 Strategic Outlook
  • 15.17 Intellia Therapeutics
    • 15.17.1 Company Snapshot
    • 15.17.2 Company Overview
    • 15.17.3 Pipeline Product Benchmarking
    • 15.17.4 Strategic Outlook
  • 15.18 2seventy bio, Inc.
    • 15.18.1 Company Snapshot
    • 15.18.2 Company Overview
    • 15.18.3 Pipeline Product Benchmarking
    • 15.18.4 Strategic Outlook

16 Conclusion and Recommendations

  • 16.1 Concluding Remarks from Visiongain
  • 16.2 Recommendations for Market Players

List of Tables

  • Table 1 CAR-T Therapy Market Snapshot, 2024 & 2034 (US$ Million, AGR %)
  • Table 2 Companion Diagnostic Market Forecast by Target Antigens, 2024-2034 (US$ Million, CAGR %, AGR %)
  • Table 3 CD19/CD22 Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 4 BCMA Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 5 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 6 Companion Diagnostic Market Forecast by Type, 2024-2034 (US$ Million, CAGR %, AGR %)
  • Table 7 Abecma Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 8 Yescarta Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 9 Kymriah Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 10 Tecartus Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 11 Other Types Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 12 Companion Diagnostic Market Forecast by Indication, 2024-2034 (US$ Million, CAGR %, AGR %)
  • Table 13 Diffuse Large B-Cell Lymphoma (DLBCL) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 14 Acute Lymphoblastic Leukaemia (ALL) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 15 Follicular Lymphoma Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 16 Multiple Myeloma (MM) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 17 Other Indication Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 18 CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, CAGR %, AGR %)
  • Table 19 Hospitals Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 20 Specialty Clinics Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 21 Other End-users Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 22 CAR-T Therapy Market Forecast by Patient, 2024-2034 (US$ Million, CAGR %, AGR %)
  • Table 23 Children Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 24 Adults Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 25 Seniors Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 26 CAR-T Therapy Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 27 North America CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Table 28 North America CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
  • Table 29 North America CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Table 30 North America CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
  • Table 31 North America CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
  • Table 32 North America CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
  • Table 33 U.S. CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 34 Canada CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 35 Europe CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Table 36 Europe CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
  • Table 37 Europe CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Table 38 Europe CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
  • Table 39 Europe CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
  • Table 40 Europe CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
  • Table 41 Germany CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 42 UK CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 43 France CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 44 Italy CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 45 Spain CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 46 Rest of Europe CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 47 Asia Pacific CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Table 48 Asia Pacific CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
  • Table 49 Asia Pacific CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Table 50 Asia Pacific CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
  • Table 51 Asia Pacific CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
  • Table 52 Asia Pacific CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
  • Table 53 China CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 54 Japan CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 55 Singapore CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 56 Australia CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 57 South Korea CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 58 Rest of Asia Pacific CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 59 Latin America CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Table 60 Latin America CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
  • Table 61 Latin America CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Table 62 Latin America CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
  • Table 63 Latin America CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
  • Table 64 Latin America CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
  • Table 65 Brazil CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 66 Mexico CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 67 Rest of Latin America CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 68 MEA CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Table 69 MEA CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
  • Table 70 MEA CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Table 71 MEA CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
  • Table 72 MEA CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
  • Table 73 MEA CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
  • Table 74 Israel CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 75 GCC CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 76 Rest of MEA CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
  • Table 77 Strategic Outlook
  • Table 78 Gilead Sciences Inc.: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 79 Gilead Sciences Inc.: Product Benchmarking
  • Table 80 Gilead Sciences Inc.: Strategic Outlook
  • Table 81 Novartis AG: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 82 Novartis AG: Product Benchmarking
  • Table 83 Novartis AG: Strategic Outlook
  • Table 84 Bristol Myers Squibb: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 85 Bristol Myers Squibb: Product Benchmarking
  • Table 86 Bristol Myers Squibb: Strategic Outlook
  • Table 87 Johnson & Johnson Services, Inc.: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 88 Johnson & Johnson Services, Inc.: Product Benchmarking
  • Table 89 AbbVie Inc.: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 90 AbbVie Inc.: Product Benchmarking
  • Table 91 AbbVie Inc.: Strategic Outlook
  • Table 92 Amgen Inc.: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 93 Amgen Inc.: Product Benchmarking
  • Table 94 BioNTech S.E.: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 95 BioNTech SE: Product Benchmarking
  • Table 96 Bluebird bio, Inc.: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 97 Bluebird bio, Inc..: Product Benchmarking
  • Table 98 Caribou Biosciences Inc.: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 99 Caribou Biosciences Inc.: Product Benchmarking
  • Table 100 Caribou Biosciences Inc.: Strategic Outlook
  • Table 101 GSK plc: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 102 GSK plc: Product Benchmarking
  • Table 103 CARsgen Therapeutics Holdings Limited: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 104 CARsgen Therapeutics Holdings Limited: Product Benchmarking
  • Table 105 CARsgen Therapeutics Holdings Limited: Strategic Outlook
  • Table 106 Pfizer Inc.: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 107 Pfizer Inc.: Product Benchmarking
  • Table 108 Pfizer Inc.: Strategic Outlook
  • Table 109 Autolus Therapeutics: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 110 Autolus Therapeutics: Product Benchmarking
  • Table 111 Autolus Therapeutics: Strategic Outlook
  • Table 112 Intellia Therapeutics: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 113 Intellia Therapeutics: Product Benchmarking
  • Table 114 Intellia Therapeutics: Strategic Outlook
  • Table 115 2seventy bio, Inc.: Key Details (CEO, H.Q., Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 116 2seventy bio, Inc.: Product Benchmarking
  • Table 117 2seventy bio, Inc.: Strategic Outlook

List of Figures

  • Figure 1 CAR-T Therapy Market Segmentation
  • Figure 2 CAR-T Therapy Market by Target Antigens: Market Attractiveness Index
  • Figure 3 CAR-T Therapy Market by Type: Market Attractiveness Index
  • Figure 4 CAR-T Therapy Market by Indication: Market Attractiveness Index
  • Figure 5 CAR-T Therapy Market by End-users: Market Attractiveness Index
  • Figure 6 CAR-T Therapy Market by Patient: Market Attractiveness Index
  • Figure 7 CAR-T Therapy Market Attractiveness Index by Region
  • Figure 8 CAR-T Therapy Market: Market Dynamics
  • Figure 9 CAR-T Therapy Market: Impact Analysis
  • Figure 10 CAR-T Therapy: Supply Chain Analysis
  • Figure 11 PEST Analysis of the CAR-T Therapy Market
  • Figure 12 CAR-T Therapy Market by Target Antigens: Market Attractiveness Index
  • Figure 13 CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
  • Figure 14 CAR-T Therapy Market Share Forecast by Target Antigens, 2024, 2029, 2034 (%)
  • Figure 15 CD19/CD22 Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 16 CD19/CD22 Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 17 BCMA Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 18 BCMA Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 19 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 20 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 21 CAR-T Therapy Market by Type: Market Attractiveness Index
  • Figure 22 CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 23 CAR-T Therapy Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 24 Abecma Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 25 Abecma Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 26 Yescarta Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 27 Yescarta Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 28 Kymriah Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 29 Kymriah Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 30 Tecartus Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 31 Tecartus Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 32 Other Types Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 33 Other Types Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 34 Companion Diagnostics Market by Indication: Market Attractiveness Index
  • Figure 35 CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
  • Figure 36 Companion Diagnostics Market Share Forecast by Indication, 2024, 2029, 2034 (%)
  • Figure 37 Diffuse Large B-Cell Lymphoma (DLBCL) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 38 Diffuse Large B-Cell Lymphoma (DLBCL) Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 39 Acute Lymphoblastic Leukaemia (ALL) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 40 Acute Lymphoblastic Leukaemia (ALL) Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 41 Follicular Lymphoma Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 42 Follicular Lymphoma Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 43 Multiple Myeloma (MM) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 44 Multiple Myeloma (MM) Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 45 Other Indication Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 46 Other Indication Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 47 CAR-T Therapy Market by End-users: Market Attractiveness Index
  • Figure 48 CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
  • Figure 49 CAR-T Therapy Market Share Forecast by End-users, 2024, 2029, 2034 (%)
  • Figure 50 Hospitals Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 51 Hospitals Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 52 Specialty Clinics Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 53 Specialty Clinics Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 54 Other End-users Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 55 Other End-users Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 56 CAR-T Therapy Market by Patient: Market Attractiveness Index
  • Figure 57 CAR-T Therapy Market Forecast by Patient, 2024-2034 (US$ Million, AGR %)
  • Figure 58 CAR-T Therapy Market Share Forecast by Patient, 2024, 2029, 2034 (%)
  • Figure 59 Children Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 60 Children Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 61 Adults Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 62 Adults Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 63 Seniors Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 64 Seniors Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 65 CAR-T Therapy Market Forecast by Region 2024 and 2034 (Revenue, CAGR%)
  • Figure 66 CAR-T Therapy Market Share Forecast by Region 2024, 2029, 2034 (%)
  • Figure 67 CAR-T Therapy Market by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 68 North America CAR-T Therapy Market Attractiveness Index
  • Figure 69 North America CAR-T Therapy Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 70 North America CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 71 North America CAR-T Therapy Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 72 North America CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
  • Figure 73 North America CAR-T Therapy Market Share Forecast by Target Antigens, 2024 & 2034 (%)
  • Figure 74 North America CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 75 North America CAR-T Therapy Market Share Forecast by Type, 2024 & 2034 (%)
  • Figure 76 North America CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
  • Figure 77 North America CAR-T Therapy Market Share Forecast by Indication, 2024 & 2034 (%)
  • Figure 78 North America CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
  • Figure 79 North America CAR-T Therapy Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 80 North America CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
  • Figure 81 North America CAR-T Therapy Market Share Forecast by Patients, 2024 & 2034 (%)
  • Figure 82 U.S. CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 83 Canada CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 84 Europe CAR-T Therapy Market Attractiveness Index
  • Figure 85 Europe CAR-T Therapy Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 86 Europe CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 87 Europe CAR-T Therapy Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 88 Europe CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
  • Figure 89 Europe CAR-T Therapy Market Share Forecast by Target Antigens, 2024 & 2034 (%)
  • Figure 90 Europe CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 91 Europe CAR-T Therapy Market Share Forecast by Type, 2024 & 2034 (%)
  • Figure 92 Europe CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
  • Figure 93 Europe CAR-T Therapy Market Share Forecast by Indication, 2024 & 2034 (%)
  • Figure 94 Europe CAR-T Therapy Market Forecast by End-user, 2024-2034 (US$ Million, AGR %)
  • Figure 95 Europe CAR-T Therapy Market Share Forecast by End-user, 2024 & 2034 (%)
  • Figure 96 Europe CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
  • Figure 97 Europe CAR-T Therapy Market Share Forecast by Patients, 2024 & 2034 (%)
  • Figure 98 Germany CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 99 UK CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 100 France CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 101 Italy CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 102 Spain CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 103 Rest of Europe CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 104 Asia Pacific CAR-T Therapy Market Attractiveness Index
  • Figure 105 Asia Pacific CAR-T Therapy Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 106 Asia Pacific CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 107 Asia Pacific CAR-T Therapy Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 108 Asia Pacific CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
  • Figure 109 Asia Pacific CAR-T Therapy Market Share Forecast by Target Antigens, 2024 & 2034 (%)
  • Figure 110 Asia Pacific CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 111 Asia Pacific CAR-T Therapy Market Share Forecast by Type, 2024 & 2034 (%)
  • Figure 112 Asia Pacific CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
  • Figure 113 Asia Pacific CAR-T Therapy Market Share Forecast by Indication, 2024 & 2034 (%)
  • Figure 114 Asia Pacific CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
  • Figure 115 Asia Pacific CAR-T Therapy Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 116 Asia Pacific CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
  • Figure 117 Asia Pacific CAR-T Therapy Market Share Forecast by Patients, 2024 & 2034 (%)
  • Figure 118 China CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 119 Japan CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 120 Singapore CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 121 Australia CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 122 South Korea CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 123 Rest of Asia Pacific CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 124 Latin America CAR-T Therapy Market Attractiveness Index
  • Figure 125 Latin America CAR-T Therapy Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 126 Latin America CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 127 Latin America CAR-T Therapy Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 128 Latin America CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
  • Figure 129 Latin America CAR-T Therapy Market Share Forecast by Target Antigens, 2024 & 2034 (%)
  • Figure 130 Latin America CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 131 Latin America CAR-T Therapy Market Share Forecast by Type, 2024 & 2034 (%)
  • Figure 132 Latin America CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
  • Figure 133 Latin America CAR-T Therapy Market Share Forecast by Indication, 2024 & 2034 (%)
  • Figure 134 Latin America CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
  • Figure 135 Latin America CAR-T Therapy Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 136 Latin America CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
  • Figure 137 Latin America CAR-T Therapy Market Share Forecast by Patients, 2024 & 2034 (%)
  • Figure 138 Brazil CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 139 Mexico CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 140 Rest of Latin America CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 141 MEA CAR-T Therapy Market Attractiveness Index
  • Figure 142 MEA CAR-T Therapy Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 143 MEA CAR-T Therapy Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 144 MEA CAR-T Therapy Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 145 MEA CAR-T Therapy Market Forecast by Target Antigens, 2024-2034 (US$ Million, AGR %)
  • Figure 146 MEA CAR-T Therapy Market Share Forecast by Target Antigens, 2024 & 2034 (%)
  • Figure 147 MEA CAR-T Therapy Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
  • Figure 148 MEA CAR-T Therapy Market Share Forecast by Type, 2024 & 2034 (%)
  • Figure 149 MEA CAR-T Therapy Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
  • Figure 150 MEA CAR-T Therapy Market Share Forecast by Indication, 2024 & 2034 (%)
  • Figure 151 MEA CAR-T Therapy Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
  • Figure 152 MEA CAR-T Therapy Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 153 MEA CAR-T Therapy Market Forecast by Patients, 2024-2034 (US$ Million, AGR %)
  • Figure 154 Middle East & Africa CAR-T Therapy Market Share Forecast by Patients, 2024 & 2034 (%)
  • Figure 155 Israel CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 156 GCC CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 157 Rest of MEA CAR-T Therapy Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 158 CAR-T Therapy Market: Company Share/Ranking, 2023
  • Figure 159 Gilead Sciences Inc.: Net Revenue, 2018-2023 (US$ Million, AGR%)
  • Figure 160 Gilead Sciences Inc.: R&D, 2018-2023 (US$ Million, AGR%)
  • Figure 161 Gilead Sciences Inc.: Regional Market Shares, 2023
  • Figure 162 Gilead Sciences Inc.: SWOT Analysis
  • Figure 163 Novartis AG: Net Revenue, 2018-2023 (US$ Million, AGR%)
  • Figure 164 Novartis AG: R&D, 2018-2023 (US$ Million, AGR%)
  • Figure 165 Novartis AG: Regional Market Shares, 2023
  • Figure 166 Novartis AG: SWOT Analysis
  • Figure 167 Bristol Myers Squibb: Net Revenue, 2018-2023 (US$ Million, AGR%)
  • Figure 168 Bristol Myers Squibb: R&D, 20180-2023 (US$ Million, AGR%)
  • Figure 169 Bristol Myers Squibb: Regional Market Shares, 2023
  • Figure 170 Bristol Myers Squibb: SWOT Analysis
  • Figure 171 Johnson & Johnson (J&J): Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 172 Johnson & Johnson (J&J): R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 173 Johnson & Johnson (J&J): Regional Market Shares, 2022
  • Figure 174 Johnson & Johnson Services, Inc.: SWOT Analysis
  • Figure 175 AbbVie Inc.: Net Revenue, 2018-2023 (US$ Million, AGR%)
  • Figure 176 AbbVie Inc.: R&D, 2018-2023 (US$ Million, AGR%)
  • Figure 177 AbbVie Inc.: Regional Market Shares, 2023
  • Figure 178 Amgen Inc.: Net Revenue, 2018-2023 (US$ Million, AGR%)
  • Figure 179 Amgen Inc.: R&D, 2018-2023 (US$ Million, AGR%)
  • Figure 180 Amgen Inc.: Regional Market Shares, 2023
  • Figure 181 BioNTech S.E.: Net Revenue, 2018-2023 (US$ Million, AGR%)
  • Figure 182 BioNTech S.E.: R&D, 2018-2023 (US$ Million, AGR%)
  • Figure 183 Bluebird bio, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 184 Bluebird bio, Inc.: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 185 Caribou Biosciences, Inc.: Net Revenue, 2019-2023 (US$ Million, AGR%)
  • Figure 186 Caribou Biosciences, Inc.: R&D, 2019-2023 (US$ Million, AGR%)
  • Figure 187 GSK plc: Net Revenue, 2018-2023 (US$ Million, AGR%)
  • Figure 188 GSK plc: R&D, 2018-2023 (US$ Million, AGR%)
  • Figure 189 GSK plc: Regional Market Shares, 2023
  • Figure 190 Pfizer: Net Revenue, 2018-2023 (US$ Million, AGR%)
  • Figure 191 Pfizer: R&D, 2018-2023 (US$ Million, AGR%)
  • Figure 192 Pfizer: Regional Market Shares, 2023